Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

Posted by on Nov 2nd, 2024

Equities research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 15.8 %

AKTX stock opened at $2.78 on Friday. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40. The business’s 50 day moving average is $3.01 and its 200-day moving average is $2.77.

Akari Therapeutics Company Profile

(Get Free Report)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.

Read More

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.